Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Cash from Financing Activities: 2010-2024

Historic Cash from Financing Activities for CorMedix (CRMD) over the last 13 years, with Dec 2024 value amounting to $26.3 million.

  • CorMedix's Cash from Financing Activities rose 969.55% to $150.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $251.2 million, marking a year-over-year increase of 1029.57%. This contributed to the annual value of $26.3 million for FY2024, which is 52.93% down from last year.
  • CorMedix's Cash from Financing Activities amounted to $26.3 million in FY2024, which was down 52.93% from $55.9 million recorded in FY2023.
  • In the past 5 years, CorMedix's Cash from Financing Activities ranged from a high of $55.9 million in FY2023 and a low of $17.9 million during FY2022.
  • Its 3-year average for Cash from Financing Activities is $33.4 million, with a median of $26.3 million in 2024.
  • Per our database at Business Quant, CorMedix's Cash from Financing Activities tumbled by 57.14% in 2022 and then soared by 212.42% in 2023.
  • Yearly analysis of 5 years shows CorMedix's Cash from Financing Activities stood at $40.1 million in 2020, then increased by 4.13% to $41.8 million in 2021, then tumbled by 57.14% to $17.9 million in 2022, then spiked by 212.42% to $55.9 million in 2023, then plummeted by 52.93% to $26.3 million in 2024.